Pharma & drug discovery · AI dealmaking
Convexia
A two person, Y Combinator backed startup that wants AI agents to do the job of a pharma business development team: find overlooked drugs, judge them, and eventually buy, trial and sell them. Today it mostly sells the diligence, not the drugs.
A pricing page instead of a pipeline
Most pharma companies open with a molecule. Convexia’s website opens with a price list. Sourcing access starts at $199 a month. A single evaluation report costs $1,497. A subscription called Convexia Pro, which adds a live roundtable of outside experts before a go or no go call, runs $2,997 a month.
That is unusual framing for a company that calls itself, in its own tagline, “the world’s first AI-maximalist pharma company.” The site itself resolves the tension in its own FAQ: the long term goal is to buy assets, run trials and sell them, but for now Convexia says “we are licensing components of our platform and running pilots with pharma, biotech, and investment groups to demonstrate value and build traction.” In other words, the pharma company is, for now, a diligence vendor to other pharma companies.
The problem, in the founders’ words
Convexia’s own description of the industry it is chasing is blunt. Its Y Combinator launch post says “pharma is the most bloated, antiquated trillion-dollar industry on the planet,” and that “life-saving drugs are overlooked, abandoned, or shelved because diligence is still done by hand.” The American Bazaar, an outlet independent of the company, repeated the same framing when it covered the July 2025 launch, describing an AI pharma firm built to buy, trial and sell drugs.
The specific gap Convexia says it is built for came into sharper focus in a May 2026 interview. Co-founder Ayaan Parikh told The Pharma Vanguard that three categories of drug assets get the least attention from traditional pharma business development teams: assets from Chinese biotechs, early-stage preclinical compounds, and programs that have already been shelved. His argument for why: the economics. “A rare disease with around 5,000 to 10,000 patient cases in the US per year will likely not return a remarkable investment for a big pharma company running a 500-person BD team,” he said. Convexia’s pitch is that a much smaller, AI-run team changes that math. “We have maybe 5 to 10% of the team that traditional pharma BD teams have, but we run everything through AI agents,” Parikh said, arguing that made even $50 to $150 million in peak sales, a number many big pharma companies would not chase, into a viable return for Convexia.
Two founders, one long partnership
Ayaan Parikh and Rahul Vijayan met at an entrepreneurship conference in eighth grade, according to the company’s own account on Y Combinator’s site, and had launched two startups together by the end of high school. At Stanford, where both studied computer science, they built a third company, which the same bio says was “recently acquired.” Convexia is described as their fourth venture. The founders’ own launch post puts it simply: they are “Stanford CS dropouts who’ve exited 3 startups together.” No source found in this research names the acquirer, the terms, or the three earlier companies themselves, so that claim stands as company-stated and unverified rather than confirmed.
Their split of duties at Convexia is consistent across sources that name it: Parikh as co-founder and, per Tracxn, chief executive; Vijayan as co-founder and chief technology officer. Both are listed as authors, under a Convexia, San Francisco affiliation, on a 2026 case study in the journal Drug Discovery Today, giving the founders a credential outside the company’s own marketing.
From diligence tool to dealmaker
Parikh described Convexia’s own arc in the same interview. “Previously, we were closer to an intelligence layer for life sciences BD and diligence,” he said. “Now we are using that infrastructure to build a hub-and-spoke pharma model around assets we believe are overlooked by traditional development economics.” He was also asked how Convexia avoids competing with the same pharma clients who pay for its diligence work. “We are very explicit about separating customer work from our internal asset strategy,” he said, adding that customer diligence stays confidential and is not used to source deals for the company itself.
What that shift looks like in practice, beyond the interview, is a single documented case. A 2026 paper in Drug Discovery Today, co-authored by researchers at institutions including the Broad Institute, Uppsala University and Convexia, describes a five-module agentic workflow Convexia built for drug asset search and evaluation, and one real engagement: “a mid-cap pharma company engaged the authors affiliation with Convexia Bio to triage its portfolio and select candidates for nomination and advancement.” The paper does not name the client, and the sentence describes the customer relationship, not an asset Convexia itself owns.
What is proven, and what is still claimed
| Evidence | What the record shows | Source type |
|---|---|---|
| Founders | Ayaan Parikh and Rahul Vijayan are named as co-founders across Y Combinator, Tracxn, PitchBook and independent press coverage of the July 2025 launch. | Independent |
| Prior startups | The founders’ own launch post says they “exited 3 startups together,” and their Y Combinator bio adds that one, built at Stanford, was “recently acquired.” No source found names an acquirer, a sale price, or the other two companies. | Not found |
| Peer-reviewed case study | Drug Discovery Today, “AI agents in drug discovery: applications and case studies” (PMID 41887499, 2026) lists Parikh and Vijayan as authors under a Convexia, San Francisco affiliation and describes an unnamed mid-cap pharma client engagement. | Public record |
| Reported funding | PitchBook, Tracxn, Caplight and VCBacked each report roughly $500,000 raised in a 2025 seed or pre-seed round, naming Y Combinator, Rebel Fund, Gaingels, Gravity Fund, Maiora Ventures and Panacea Capital as investors. Caplight elsewhere lists total funding as $1M on the same profile page. | Aggregators disagree |
| SEC filing | No Form D or other filing for a company named Convexia appears in SEC EDGAR’s company search or in EDGAR full text search of Form D filings, checked Sep 25, 2026. | Not found |
| FDA, trials, federal grants, patents | No FDA 510(k) or PMA record, no registered clinical trial, no NIH or NSF award, and no assigned US patent were found under Convexia’s name. | Not found |
| A named drug asset | Convexia says its long term goal is to acquire, trial and sell drugs, and describes targeting rare disease and China-originated programs. No specific licensed-in or acquired drug, indication or counterparty has been publicly named. | Company-stated |
Read plainly: the strongest evidence for Convexia is that it exists, has two named founders with a shared history, and has put its own methodology into a peer-reviewed paper describing a real, if anonymous, paying customer. Everything about drugs Convexia will itself own, from the first named asset to the first Form D, has not happened yet, at least not in public.
What to watch
- Whether Convexia names its first licensed-in or acquired drug asset, and who the licensor is.
- A first SEC Form D or other primary filing that would confirm the roughly $500,000 several data aggregators already report.
- Named customers beyond the anonymized “mid-cap pharma company” described in the Drug Discovery Today case study.
- Whether the rare disease, hub and spoke acquisition strategy Parikh described in May 2026 produces an actual deal.
In their words
“Pharma is the most bloated, antiquated trillion-dollar industry on the planet.”
Convexia launch post, Y Combinator, July 2025 · Company
“Stanford CS dropouts who’ve exited 3 startups together.”
Ayaan Parikh and Rahul Vijayan, launch post, July 2025 · Company
“A rare disease with around 5,000 to 10,000 patient cases in the US per year will likely not return a remarkable investment for a big pharma company running a 500-person BD team.”
Ayaan Parikh, co-founder, The Pharma Vanguard, May 2026 · Interview
“We have maybe 5 to 10% of the team that traditional pharma BD teams have, but we run everything through AI agents.”
Ayaan Parikh, The Pharma Vanguard, May 2026 · Interview
“We are very explicit about separating customer work from our internal asset strategy.”
Ayaan Parikh, The Pharma Vanguard, May 2026 · Interview
“Programs which might otherwise remain shelved can move toward patients, especially where the patient population is meaningful but the commercial opportunity is too small for traditional pharma infrastructure.”
Ayaan Parikh, The Pharma Vanguard, May 2026 · Interview
“we are licensing components of our platform and running pilots with pharma, biotech, and investment groups to demonstrate value and build traction.”
Convexia website, frequently asked questions, accessed Sep 25, 2026 · Company
Related companies
Sources
- Public recordPubMed, AI agents in drug discovery: applications and case studies, PMID 41887499
- Public recordAI Agents in Drug Discovery, full text (arXiv preprint of the same paper)
- Public recordSEC EDGAR company search, query “convexia,” Form D
- Public recordSEC EDGAR full text search, “Convexia,” Form D filings
- Independent‘AI-maximalist’ pharma firm Convexia, backed by Y Combinator, officially debuts
- InterviewConvexia Bio: AI Agents Rescuing Abandoned Pharma Assets
- IndependentConvexia company profile
- IndependentConvexia funding and investors
- IndependentConvexia valuation and funding history
- IndependentConvexia funding and investors
- IndependentConvexia revenue estimate, $220K
- CompanyConvexia: The world’s first AI-maximalist pharma company
- CompanyConvexia website, product and pricing pages
- CompanyConvexia Launches: World’s First AI-Maximalist Pharma Company
- CompanyConvexia organization profile
Profile researched and written by Healthcare Discovery. Last updated September 29, 2026.
